NervGen Pharma Corp. (NGEN)

NASDAQ: NGEN · USD

$1.32

-0.03 (-2.2%)· Recorded snapshot

Market cap	141.9M
Net income (ttm)	-15.7M
EPS (ttm)	-$0.46
Shares out	107.5M
Volume	418,314.101
Beta	0.82

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -15.7M
EPS (ttm): -$0.46
Market cap: 141.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-96.8

P25 n/aP50 n/aP75 n/a

ROIC-88.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NGEN indicators

Market & fundamental data

Available fields

175

Groups with data

Currency

CAD

Showing 175 of 175 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001751912
Company name	NervGen Pharma Corp.
Country	Canada
Country code	US
CUSIP number	64082X203
Earnings date	2026-11-18
Earnings time	bmo
Employees	10
Enterprise value	$80.8M
Exchange	NASDAQ
Financial currency	CAD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2017
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	CA64082X2032
Last earnings date	2026-08-13
Last refreshed	2026-11-04
Last stock split type	Never
Market cap	$141.9M
Market cap category	Micro-Cap
Next earnings date	2026-11-18
Options	Yes
Price	$1.32
Price currency	USD
Sector	Healthcare
Stock price date	2026-11-03
Symbol	NGEN
Website	https://nervgen.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-34.62%
FCF / EV yield	-22.78%
FCF yield	-12.97%
P/B ratio	4.26x
Price / tangible book value	4.34x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.6M
Profitable quarters	1
ROA	-38.04%
ROA (5Y)	-72.71%
ROCE	-69.58%
ROE	-96.84%
ROE (5Y)	-2,128.7%
ROIC	-88.61%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth quarters	2
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$40,047
EBIT	$-23M
EBITDA	$-22.9M
EPS	$-0.46
FCF per share	$-0.17
Financing cash flow	$69.5M
Free cash flow	$-18.4M
Free cash flow minus SBC	$-22.6M
Investing cash flow	$41,458
Net borrowing	$-42,257
Net cash flow	$50.1M
Net income	$-15.7M
Operating cash flow minus SBC	$-22.6M
Operating income	$-23M
Stock-based compensation	$4.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.31
Debt / equity	0
Long-term assets	$-950,655
Long-term liabilities	$-588,461
Net cash (debt)	$61.1M
Net cash / market cap	43.06%
Net cash growth	455.74%
Net debt / equity	-1.85
Piotroski F-Score	1
Shareholders' equity	$33M
Tangible book value	$32.7M
Tangible book value per share	$0.31
Total assets	$63.5M
Total cash	$61.1M
Total debt	$0
Total liabilities	$30.5M
WACC	8.78%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$64.5M
Current liabilities	$31.1M
Current ratio	2.07
Net working capital	$-28.4M
Quick ratio	2.01
Working capital	$32.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-13.43%
Dividend yield	0%
Shareholder yield	-13.43%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.35
1D price change	-2.22%
1M price change	-25.84%
1M total return	-25.84%
1W price change	-10.81%
1W total return	-10.81%
1Y price change	-46.77%
1Y return CAGR	-46.8%
1Y total return	-46.77%
20-day SMA	$1.53
200-day SMA	$2.80
3M price change	-18.52%
3M total return	-18.52%
3Y price change	-0.6%
3Y return CAGR	-0.2%
3Y total return	-0.6%
50-day SMA	$1.87
50-day SMA vs 200-day SMA	50under200
52-week high	$6.30
52-week high date	2026-01-08
52-week low	$1.28
52-week low date	2026-11-03
5Y price change	-42.36%
5Y return CAGR	-10.43%
5Y total return	-42.36%
6M price change	-65.08%
6M total return	-65.08%
After-hours change	-0.38%
After-hours close	$1.32
After-hours price	$1.32
All-time high	$6.30
All-time high date	2026-01-08
All-time low	$0.55
All-time low date	2020-03-25
Average true range (ATR)	$0.11
Average volume	455.5K
Beta (1Y)	2.15
Beta (2Y)	0.62
Beta (5Y)	0.82
Change from 52-week high	-79.05%
Change from 52-week low	3.13%
Change from all-time high	-79.05%
Change from all-time low	139.91%
Change from open	-2.22%
Day's gap	0%
Dollar volume	$552,175
High price	$1.37
Low price	$1.28
Monthly RSI	41.11
Open price	$1.35
Position in 52-week range	47.06%
Premarket change	4.55%
Premarket close	$1.32
Premarket price	$1.38
Premarket volume	720
Previous close	$1.35
Price vs 150-day SMA	-43.88%
Price vs 20-day SMA	-13.89%
Price vs 200-day SMA	-52.89%
Price vs 50-day SMA	-29.26%
Relative volume	0.92
RSI	26.1
Sharpe ratio	-0.35
Sharpe ratio (3Y)	0.35
Sharpe ratio (5Y)	0.17
Sortino ratio	-0.41
Sortino ratio (3Y)	0.61
Sortino ratio (5Y)	0.34
Volume	418.3K
Weekly RSI	29.97
YTD price change	-76.43%
YTD total return	-76.43%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	95.3M
Float percentage	88.63%
Shares change (QoQ)	29.98%
Shares change (YoY)	13.43%
Shares held by insiders	2.07%
Shares held by institutions	14.01%
Shares outstanding	107.5M
Short % of float	5.34%
Short % of shares	4.73%
Short ratio	10.1 days

Deeper analysis on NGEN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NGEN report

Is a complete NGEN research report available?

No complete published report is available for NervGen Pharma Corp. (NGEN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

NervGen Pharma Corp. (NGEN)

Price

Financial snapshot

Fair-value bridge

Latest news · NGEN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NGEN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NGEN

Frequently asked questions